Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...
“Most importantly, with a strong clinical profile and as the only product approved for the treatment of [cold agglutinin disease], Enjaymo addresses a serious unmet medical need for patients ...
GlobalData on MSN3d
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo"Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo" was originally created and published by Pharmaceutical ...
The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (EPA: SASY) (NASDAQ: SNY) to buy the global ...
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback